Dash Bio Secures $11M to Enhance Automated Bioanalysis Platform

Dash Bio has raised an additional $11 million in funding, bringing its total funding to $17.5 million, announced in a press release. The funding round was led by The Aligned Fund, with participation from Freestyle Capital, Cybernetix Ventures, Swift Ventures, LifeX Ventures, Drive Capital, and others.

Dash Bio is focused on revolutionizing drug development through its fully automated, GLP-compliant bioanalysis platform. The company aims to address the bottlenecks in drug development by offering assays like ELISA, LC-MS, and qPCR at speeds up to 10 times faster than traditional providers. This approach is designed to help drug developers move from idea to approval more efficiently.

The new funding will be used to scale Dash Bio's automated platform, expand its assay menu, and invest in proprietary sample and assay management software. The company plans to onboard new customers from preclinical through late-stage clinical development, further enhancing its impact on the biotech industry.